Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.65 |
| ▸ | ESRRG | P62508 | 9/20 | 0.63 |
| ▸ | ESRRB | O95718 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151879 | 1.00 | ESR1 (0.71) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL1151987 | 1.00 | ESR1 (0.71) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL2229348 | 1.00 | ESR1 (0.71) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL1151880 | 1.00 | ESR1 (0.71) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL5725055 | 1.00 | ESR1 (0.71) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL5726578 | 0.92 | ESR1 (0.61) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL11206207 | 0.92 | ESR1 (0.61) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL5725960 | 0.92 | ESR1 (0.61) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL11206212 | 0.92 | ESR1 (0.61) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL5725955 | 0.92 | ESR1 (0.61) | ESR1ESR2CYP19A1ESRRGESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6056724-A | — | — | None | — | — | JP | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| JP-H0656724-A | PREPARATION OF NEW ALKENE DERIVATIVE | FARMOS YHTYMAE OY | 1994-03-01 | — | — | JP | disclosed |
| US-4996225-A | Antitumor agents | FARMOS GROUP LTD. (FI) | 1991-02-26 | — | — | US | disclosed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | disclosed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885ESR2 4164/4885CYP19A1 4479/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885ESR2 4164/4885CYP19A1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.